These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 17456513)

  • 1. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Futility interim monitoring with control of type I and II error probabilities using the interim Z-value or confidence limit.
    Lachin JM
    Clin Trials; 2009 Dec; 6(6):565-73. PubMed ID: 19933716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping clinical trials early for benefit: impact on estimation.
    Freidlin B; Korn EL
    Clin Trials; 2009 Apr; 6(2):119-25. PubMed ID: 19342463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim futility analysis with intermediate endpoints.
    Goldman B; LeBlanc M; Crowley J
    Clin Trials; 2008; 5(1):14-22. PubMed ID: 18283075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current controversies in data monitoring for clinical trials.
    Pocock SJ
    Clin Trials; 2006; 3(6):513-21. PubMed ID: 17170035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and analysis of group sequential clinical trials with multiple primary endpoints.
    Kosorok MR; Yuanjun S; DeMets DL
    Biometrics; 2004 Mar; 60(1):134-45. PubMed ID: 15032783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new and rapid scoring system to assess the scientific evidence from clinical trials.
    Silber S
    J Interv Cardiol; 2006 Dec; 19(6):485-92. PubMed ID: 17107362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fitting spending functions.
    Anderson KM; Clark JB
    Stat Med; 2010 Feb; 29(3):321-7. PubMed ID: 19842091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of the Data and Safety Monitoring Committee (DSMC).
    Wilhelmsen L
    Stat Med; 2002 Oct; 21(19):2823-9. PubMed ID: 12325098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm.
    Goldman AI; Hannan PJ
    Stat Med; 2001 Jun; 20(11):1575-89. PubMed ID: 11391689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-ruling a group sequential boundary--a stopping rule versus a guideline.
    Lan KK; Lachin JM; Bautista O
    Stat Med; 2003 Nov; 22(21):3347-55. PubMed ID: 14566919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Power and sample size when multiple endpoints are considered.
    Senn S; Bretz F
    Pharm Stat; 2007; 6(3):161-70. PubMed ID: 17674404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring rare serious adverse events from a new treatment and testing for a difference from historical controls.
    Fay MP; Huang CY; Twum-Danso NA
    Clin Trials; 2007; 4(6):598-610. PubMed ID: 18042569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.